Trajectories and predictors of financial toxicity in breast cancer patients: A multicenter longitudinal study in China

IF 7.9 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Breast Pub Date : 2025-03-13 DOI:10.1016/j.breast.2025.104441
Yi Kuang , Jiajia Qiu , Ye Liu , Sijin Guo , Ting Chen , Lichen Tang , Winnie K.W. So , Weijie Xing
{"title":"Trajectories and predictors of financial toxicity in breast cancer patients: A multicenter longitudinal study in China","authors":"Yi Kuang ,&nbsp;Jiajia Qiu ,&nbsp;Ye Liu ,&nbsp;Sijin Guo ,&nbsp;Ting Chen ,&nbsp;Lichen Tang ,&nbsp;Winnie K.W. So ,&nbsp;Weijie Xing","doi":"10.1016/j.breast.2025.104441","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patients with breast cancer experience varying levels of financial toxicity (FT), but the factors contributing to sustained financial toxicity remain poorly understood.</div></div><div><h3>Methods</h3><div>This longitudinal study was conducted from November 2022 to March 2024 in China. Participants were recruited from four Tertiary Level A hospitals using convenient sampling. FT was assessed using the Comprehensive Score for Financial Toxicity (COST) at baseline (T1), 3 months (T2), 6 months (T3), and 12 months (T4) post-surgery. Growth Mixture Modeling was used to identify the different trajectories of the FT. Multivariable logistic regression were employed to explore the predictive factors with different trajectory categories.</div></div><div><h3>Results</h3><div>Among 378 participants (all women; median [SD] age, 48.9 [9.97] years), the COST score was lowest at T2. Three distinct FT trajectories were identified: 91 patients <strong>(24 %)</strong> in the \"Severe FT with Gradual Relief\" group (trajectory 1), 190 patients <strong>(50 %)</strong> in the \"Persistently Low-Level FT\" group (trajectory 2), and 97 patients <strong>(</strong>26 %<strong>)</strong> in the \"Moderate FT with Gradual Worsening\" group (trajectory 3). Using trajectory 2 as the reference, predictors for trajectory 1 included symptom burden, location, cancer stage, cost-related health literacy, resilience, and difficulty affording basic expenses. For trajectory 3, predictors included monthly household income, symptom burden, location, and cancer stage.</div></div><div><h3>Conclusions</h3><div>The FT experienced by breast cancer patients changes over time and follows distinct dynamic trajectories, influenced by multiple factors. In future clinical practice, early identification and intervention for high-risk FT groups should be prioritized.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"81 ","pages":"Article 104441"},"PeriodicalIF":7.9000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977625004588","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Patients with breast cancer experience varying levels of financial toxicity (FT), but the factors contributing to sustained financial toxicity remain poorly understood.

Methods

This longitudinal study was conducted from November 2022 to March 2024 in China. Participants were recruited from four Tertiary Level A hospitals using convenient sampling. FT was assessed using the Comprehensive Score for Financial Toxicity (COST) at baseline (T1), 3 months (T2), 6 months (T3), and 12 months (T4) post-surgery. Growth Mixture Modeling was used to identify the different trajectories of the FT. Multivariable logistic regression were employed to explore the predictive factors with different trajectory categories.

Results

Among 378 participants (all women; median [SD] age, 48.9 [9.97] years), the COST score was lowest at T2. Three distinct FT trajectories were identified: 91 patients (24 %) in the "Severe FT with Gradual Relief" group (trajectory 1), 190 patients (50 %) in the "Persistently Low-Level FT" group (trajectory 2), and 97 patients (26 %) in the "Moderate FT with Gradual Worsening" group (trajectory 3). Using trajectory 2 as the reference, predictors for trajectory 1 included symptom burden, location, cancer stage, cost-related health literacy, resilience, and difficulty affording basic expenses. For trajectory 3, predictors included monthly household income, symptom burden, location, and cancer stage.

Conclusions

The FT experienced by breast cancer patients changes over time and follows distinct dynamic trajectories, influenced by multiple factors. In future clinical practice, early identification and intervention for high-risk FT groups should be prioritized.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺癌患者财务毒性的轨迹和预测因素:中国的一项多中心纵向研究
背景乳腺癌患者经历不同程度的财务毒性(FT),但导致持续财务毒性的因素仍然知之甚少。方法本研究于2022年11月至2024年3月在中国进行。采用方便抽样的方法从四家三级甲等医院招募参与者。在术后基线(T1)、3个月(T2)、6个月(T3)和12个月(T4)使用财务毒性综合评分(COST)评估FT。采用生长混合模型识别FT的不同轨迹,采用多变量逻辑回归分析不同轨迹类别的预测因素。结果378名参与者(均为女性;中位[SD]年龄48.9[9.97]岁),T2时COST评分最低。确定了三种不同的FT轨迹:91名患者(24%)属于“逐渐缓解的严重FT”组(轨迹1),190名患者(50%)属于“持续低水平FT”组(轨迹2),97名患者(26%)属于“逐渐恶化的中度FT”组(轨迹3)。以轨迹2为参考,轨迹1的预测因子包括症状负担、位置、癌症分期、与成本相关的健康知识、恢复力和负担基本费用的困难。轨迹3的预测因子包括家庭月收入、症状负担、地点和癌症分期。结论乳腺癌患者的FT随时间变化,具有明显的动态轨迹,受多种因素影响。在今后的临床实践中,应优先对FT高危人群进行早期识别和干预。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Breast
Breast 医学-妇产科学
CiteScore
8.70
自引率
2.60%
发文量
165
审稿时长
59 days
期刊介绍: The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.
期刊最新文献
Risk Stratified Breast Cancer Screening: Early Outcomes and Psychological Impact from PRSONAL - a Randomized Clinical Trial. A complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trial. BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer. Biomarker recall and understanding among people living with metastatic breast cancer - results from an international patient survey. Late distant recurrence prediction model in premenopausal women with ER-positive/HER 2-negative breast cancer: A multicenter retrospective study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1